Structure Therapeutics Inc. (NASDAQ:GPCR) Targets Obesity with Promising Drug
Structure Therapeutics(US:GPCR) Financial Modeling Prep·2026-01-20 06:00Goldman Sachs sets a price target of $102 for NASDAQ:GPCR, indicating a potential increase of approximately 15.07%.Aleniglipron demonstrates a clinically meaningful weight loss of 11.3% in Phase 2b study.The company faces challenges from adverse events and competition from compounded drugs.Structure Therapeutics Inc. (NASDAQ:GPCR) is a biopharmaceutical company focused on developing innovative treatments for obesity. The company is currently seeking approval for its experimental weight-loss pill, aleniglipr ...